Risk factor
Low default risk
Profitability factor
Very strong margins and returns
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.1% | -0.12% |
| Steven Cohen | Point72 Asset Management, L.P. | 0.1% | +0.05% |
About
Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian territories, including Mainland China, Hong Kong, and Taiwan. The company's activities are divided into two main categories: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division offers therapeutic solutions for conditions such as diabetes, obesity, cardiovascular health, and other developing medical areas. Meanwhile, the Rare Disease division provides treatments for unusual blood conditions, uncommon endocrine disorders, and hormone replacement therapies. Beyond its drug portfolio, Novo Nordisk also manufactures medical devices like insulin pens, growth hormone pens, and injection needles. Furthermore, it develops intelligent tools for diabetes management, including advanced smart insulin pens and the Dose Check application, designed to assist with insulin dosage guidance. The company holds a cooperative agreement with Aspen Pharmaceuticals for the manufacturing of insulin products. Novo Nordisk A/S was founded in 1923 and its corporate headquarters are located in Bagsvaerd, Denmark.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of NOVO-B.CO is 297 and suggests 2.78% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation